Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

KELOWNA, BC / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3. “The main purpose of the study was to confirm that Lexaria’s DehydraTECH formulation and processing methodology did not negate the known antiviral efficacy of these compounds before proceeding to larger, planned in vivo efficacy testing, said Chris Bunka, CEO of Lexaria Bioscience Corp. “These preliminary findings evidenced SARS-CoV-2 inhibitory performance commensurate with our expectations warranting ongoing and further investigation in animal testing.” This study used one of the most widely applied and informative predictive measures of drug efficacy to measure the half-maximal inhibitory concentration (“IC50”) of the drugs when formulated with DehydraTECH. This was an important step towards advancing to animal and ultimately human efficacy testing for the purpose of using DehydraTECH-processed drugs to treat COVID-19. This study was performed using a primate cell line, VERO-E6, and conducted by a leading independent, US biosafety level 3 testing laboratory that delivers critical services to government and commercial customers. That third party laboratory was responsible for study administration, quality control, and generation of results. Lexaria President John Docherty, Head of R&D, has verified the information within this press release. Lexaria’s antiviral study program may also have benefits beyond COVID-19, including a wide range of other viral disease indications where improved oral delivery performance is needed. The combined market for antiviral drugs is projected to be over USD $44 billion by 2026. 1 Remdesivir and ebastine have each shown promise in the fight against COVID-19. Remdesivir is a well-known nucleotide reverse transcriptase inhibitor, available under the trade name Veklury® from Gilead Sciences Inc., that interferes with the SARS-CoV-2 viral replication life cycle and has received emergency use authorization in many regions of the world for treatment of COVID-19 2 . Ebastine is an antihistamine drug that has potent effects in inhibiting the SARS-CoV-2 main protease (Mpro, also called the 3CL protease) blocking viral entry into human cells 3 , together with effects to reduce COVID-19 inflammatory reactions 4 . Mpro inhibitors are gaining attention in the fight against COVID-19, as announced by Pfizer with their novel compound PF-07304814 5 . Both remdesivir and ebastine are characterized by poor aqueous solubility and compromised intestinal absorption and bioavailability when administered orally. Lexaria hopes that its patented DehydraTECH delivery technology will pave the way for better performing oral dosage forms of these and other antiviral drugs, as it has already demonstrated for a range of lipophilic drug molecules including other antiviral agents such as darunavir and efavirenz as previously announced. Lexaria is currently investigating the pharmacokinetic performance of remdesivir and ebastine in its ongoing animal study VIRAL-A20-2, as well as other antiviral drugs of interest against SARS-CoV-2 in its additional ongoing animal study VIRAL-A20-3. The Company will release results from these studies as well as plans for future in vivo efficacy modelling as they become available. The Company is interested in pursuing strategic collaboration opportunities with established pharmaceutical industry partners who may be interested in incorporating DehydraTECH technology with antiviral drugs including and/or similar to those that are currently being investigated. The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. 1 https://www.globenewswire.com/news-release/2020/02/20/1987756/0/en/Antiviral-Drugs-Market-Worth-USD-44-2-billion-by-2026-at-3-2-CAGR-Rising-Prevalence-of-HIV-to-Fuel-Growth-Fortune-Business-Insights.html 2 https://www.nih.gov/news-events/nih-research-matters/final-report-confirms-remdesivir-benefits-covid-19 3 https://www.researchgate.net/publication/341660698_Targeting_the_SARS-CoV-4 4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472874/ 5 https://cen.acs.org/pharmaceuticals/drug-discovery/Pfizers-novel-COVID-19-antiviral/98/web/2020/09 About Lexaria Bioscience Corp. Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 19 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com . CAUTION REGARDING FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants, or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the U.S. Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure, or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise, except as otherwise required by law. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. INVESTOR CONTACT: [email protected] Phone: 866-221-3341 SOURCE: Lexaria Bioscience Corp. View source version on accesswire.com: https://www.accesswire.com/650217/Lexarias-DehydraTECHTM-Enabled-Remdesivir-and-Ebastine-Effectively-Inhibit-the-COVID-19-SARS-CoV-2-Virus 0 Comments Author mmcdonald Leave a Reply Cancel reply Your email address will not be published. Comment You may use these <abbr title="HyperText Markup Language">html</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Search for: Categories Press Releases 225 Recent Posts Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds September 9, 2026 Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds September 8, 2026 Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference September 4, 2026 Lexaria Receives USD$2.6 Million Tax Rebate Payment September 1, 2026 DehydraTECH™-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria’s 2026 Animal Study #2 August 24, 2026 Archives September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 July 2021 June 2021 May 2021 April 2021 March 2021 February 2021 January 2021 Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. 250.765.6424 [email protected] Canadian Operations #100-740 McCurdy Road Kelowna, BC, V1X2P7 US Operations 210 Shamrock Industrial Blvd., Suite C Tyrone, GA 30290 Australia Operations C/o Lexaria (AU) Pty Ltd Suite 1 Level 3, 62 Lygon Street Carlton South, VIC 3053 Privacy Policy General Disclaimer: No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases… Read More Copyright © 2024 Lexaria Bioscience . All rights reserved.

The release as fetched from its publisher. lexariabioscience.com ↗